EDCR has started – first patient included in new study combining the diabetes vaccine Diamyd® with etanercept

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that the first patient has been included in a new study, EDCR, in which the diabetes vaccine Diamyd® will be combined with two other approved agents, the immunosuppressive drug etanercept and vitamin D, with the aim to evaluate the safety of the combination treatment as well as its impact on the immune system in children and adolescents newly diagnosed with type 1 diabetes. With the start of EDCR a total of six clinical studies are now ongoing where alternative approaches with Diamyd® are being tested, either in